Sugi Predict
/ Targets
/ CDK7
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to CDK7 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt |
PHASE4 | COMPLETED |
| Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer |
PHASE4 | NOT_YET_RECRUITING |
| A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) |
PHASE3 | COMPLETED |
| The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study |
PHASE3 | RECRUITING |
| Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer |
PHASE3 | ACTIVE_NOT_RECRUITING |
| Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression |
PHASE2 | COMPLETED |
| To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy |
PHASE2 | COMPLETED |
| Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 |
PHASE2 | RECRUITING |
| CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) |
PHASE1/PHASE2 | RECRUITING |
| Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer |
PHASE2 | RECRUITING |
| A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors |
PHASE1/PHASE2 | COMPLETED |
| Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer |
PHASE2 | COMPLETED |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | UNKNOWN |
| Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma |
PHASE1/PHASE2 | RECRUITING |
| Histology-Independent Study of Palbociclib in Patients With Advanced Cancer |
PHASE2 | WITHDRAWN |
| Abemaciclib + Pembrolizumab In Glioblastoma |
PHASE2 | WITHDRAWN |
| Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer |
PHASE1/PHASE2 | RECRUITING |
| Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma |
PHASE1 | COMPLETED |
| A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy |
PHASE1 | NOT_YET_RECRUITING |
| A Study of PRT2527 in Participants With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer |
PHASE1 | NOT_YET_RECRUITING |
| Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) |
PHASE1 | COMPLETED |
| TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy |
PHASE1 | RECRUITING |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period |
nan | UNKNOWN |
| The SONImage Study |
nan | ACTIVE_NOT_RECRUITING |
| Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy |
nan | COMPLETED |
| Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a CDK7 binder may also engage these)